Global Antibiotic Development Faces Critical Shortage Amid Rising Superbug Threats

The global pipeline for new antibiotics to combat superbugs has significantly diminished, with a reported 35% decrease in antimicrobial projects from major pharmaceutical companies over the past five years. According to a report by the Access to Medicine Foundation (AMF), the number of medicines in development has dropped from 92 to 60, raising concerns about the future of public health. Experts predict that annual deaths linked to drug-resistant infections could double to 8 million by 2050, exacerbating an already dire situation where over 1 million people die each year directly from these infections.

The Guardian

Among the pharmaceutical companies, the UK's GSK is leading the charge with 30 ongoing projects aimed at developing new antimicrobials. Other notable contributors include Japan's Shionogi and Otsuka. In contrast, AstraZeneca is not involved in antibiotic development, as infectious diseases have never been its primary focus. The report highlights that only five medicines are currently in development for children under five, a demographic particularly vulnerable to infections.

The Guardian

Despite the overall decline in antibiotic development, there have been some recent successes. Three new antibiotics have been approved, including GSK's Blujepa for uncomplicated urinary tract infections and Innoviva's Nuzolvence for gonorrhea. These approvals mark significant advancements, as they are the first new treatments for these conditions in decades. Jayasree K Iyer, CEO of AMF, emphasized the urgency of the situation, stating, “There is no time to lose,” and underscoring the need for responsible antibiotic use and waste management.

The Guardian

Critics argue that pharmaceutical companies have a moral obligation to invest in antibiotic research, particularly as drug resistance poses a growing threat to healthcare. Lord Ara Darzi, a prominent cancer surgeon, noted that infection is the second-largest killer of cancer patients, highlighting the consequences of inadequate antibiotic development. He stated, “You don’t win a game if you have three good strikers and your defence is weak,” referring to the need for robust antimicrobial defenses alongside advancements in cancer treatment.

The Guardian

John-Arne Røttingen, CEO of the Wellcome Trust, described the lack of effective antibiotics as a “big challenge for society.” He advocated for innovative solutions, such as the European Commission's proposal for transferable exclusivity vouchers, which would provide antimicrobial developers with an additional 12 months of data protection. Furthermore, he suggested that the NHS's subscription model for antibiotics, which guarantees revenue for drugmakers, should be adopted by other high-income countries to incentivize antibiotic development.

The Guardian

While the AMF report presents a grim outlook on antibiotic development, it also indicates that recent approvals demonstrate potential for progress. However, the overall decline in research investment raises questions about the sustainability of these advancements. The discrepancy between the urgent need for new antibiotics and the pharmaceutical industry's response remains a critical concern.

The Guardian

• “Overall, the research and development pipeline remains worryingly thin, and industry investment has lost momentum,” — Jayasree K Iyer, CEO, Access to Medicine Foundation

The Guardian

• “You don’t win a game if you have three good strikers and your defence is weak.” — Lord Ara Darzi, Executive Chair, Fleming Initiative

The Guardian

• “There is no time to lose,” — Jayasree K Iyer, CEO, Access to Medicine Foundation

The Guardian

• “John-Arne Røttingen, the chief executive of the Wellcome Trust, said the lack of effective antibiotics was a “big challenge for society”.” — John-Arne Røttingen, CEO, Wellcome Trust

The Guardian